Novartis Oncology Turkey and Eczacıbaşı İlaç Pazarlama A.Ş. Signed the Cooperation Contract
Novartis Oncology Turkey and Eczacıbaşı İlaç Pazarlama A.Ş., which operates in the fields of hospital products, dermatology, urology, gastroenterology, pediatrics, consumer health and oncology with it is 350 employees, signed a joint cooperation contract that places the patient and operational efficiency at the focal point.
Within the framework of the contract; Novartis Oncology Turkey has granted the sales, promotion and distribution rights of Acromegaly,
NET, GİST, KML and three products in Lung Cancer treatment area (by keeping their licenses in Novartis) in Turkey and the TRNC to Eczacıbaşı İlaç Pazarlama A.Ş. for a limited period as of August 1, 2019.
Pınar Üstündağ, General Manager of Novartis Oncology Turkey, stated that: “As Novartis Oncology, we continue to develop and deliver innovative oncology medicines to meet the medical needs of patients with cancer and related diseases.
In this frame; we have one of the largest global portfolios with over 20 products for more than 25 diseases in the field of oncology, hematology and rare diseases.
In parallel with the ever-increasing development and value-added needs in the pharmaceutical sector, we evaluate our responsibility in this area with the support to the cooperation, employment, national economy and R&D capacity for the targeted improvements in public health.
” Canan Bademlioğlu, General Director of Eczacıbaşı İlaç Pazarlama A.Ş., stated that; “For more than 70 years, we have been strengthening our patient-oriented approach through corporations with leading organizations around the world and contributing to the right treatment of patients in our country.
This important agreement with Novartis Oncology enhances our belief in this cooperation with its compliance with our long-standing history, our responsibility to patients and society, and our corporate vision.
For this reason, we consider our strategic cooperation as one of the important milestones of our goal of contributing to the treatment of oncology patients based on their needs.”
